volume 9, issue 3, P94-96 2013
DOI: 10.1177/1747016113502276
View full text
|
|
Share

Abstract: Following recent revelations about drug companies withholding clinical trial evidence from drug regulators which provide licences for the sale of drugs and, despite there being heavy regulations in this area, the BMJ has launched a consistent and sustained campaign for more open data with a focus on the following drugs: Tamiflu and Relenza, both to treat influenza, Incretin mimetics and Rosiglitazone (Avandia), both to treat type 2 diabetes, and Rofecoxib (Vioxx) for osteoarthritis.The case for regulators havi…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals